<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04973670</url>
  </required_header>
  <id_info>
    <org_study_id>ZDHL</org_study_id>
    <nct_id>NCT04973670</nct_id>
  </id_info>
  <brief_title>Protective Effect of Sivelestat Sodium on ARDS in Patients With Sepsis</brief_title>
  <official_title>Protective Effect of Sivelestat Sodium on ARDS in Patients With Sepsis: Multicenter, Random, Double-blind, Parallel, Placebo Control Clinical Trials</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Southeast University, China</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Southeast University, China</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Sivelestat sodium has been approved for use in patients with SIRS and ALI, but whether it can&#xD;
      protect patients with sepsis from developing ARDS remains unknown.The aim of this study was&#xD;
      to determine whether sivelestat sodium has a protective effect on ARDS in patients with&#xD;
      sepsis.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study was conducted in accordance with good clinical practice and with the guidelines set&#xD;
      out in the Declaration of Helsinki. After approval from local and national ethics committees,&#xD;
      patients from 3 centers in China were recruited.&#xD;
&#xD;
      All patients were randomized, in a double-blind manner, to receive either sivelestat sodium&#xD;
      regimen or a placebo regimen for 1- 7 days in ICU.&#xD;
&#xD;
      The aim of this study was to determine whether sivelestat sodium has a protective effect on&#xD;
      ARDS in patients with sepsis.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 11, 2021</start_date>
  <completion_date type="Anticipated">October 30, 2023</completion_date>
  <primary_completion_date type="Anticipated">September 30, 2023</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Progression to ARDS within 7 days (Berlin criteria)</measure>
    <time_frame>From study drug administration to days 7</time_frame>
    <description>The proportion of patients with sepsis progressing to ARDS</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Oxygenation index (PaO2/FiO2) or SpO2 / FiO2 on day 1, 3 and 7 from drug administration</measure>
    <time_frame>From study drug administration to days 7</time_frame>
    <description>PaO2/FiO2 or SpO2 / FiO2 was recorded on day 1, 3 and 7 from drug administration</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Concentration of inflammatory factors on day 1, 3 and 7 from drug administration</measure>
    <time_frame>From study drug administration to days 7</time_frame>
    <description>Inflammatory factors include Interleukin(IL)-1β,IL-6, IL-8, IL-10, tumor necrosis factor(TNF)-α</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Concentration of neutrophil elastase on day 1, 3 and 7 from drug administration</measure>
    <time_frame>From study drug administration to days 7</time_frame>
    <description>Concentration of neutrophil elastase was recorded on day 1, 3 and 7 from drug administration</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Platelet count on day 1, 3 and 7 from drug administration</measure>
    <time_frame>From study drug administration to days 7</time_frame>
    <description>Platelet count was recorded on day 1, 3 and 7 from drug administration</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Concentration of C-reactive protein on day 1, 3 and 7 from drug administration</measure>
    <time_frame>From study drug administration to days 7</time_frame>
    <description>Concentration of High sensitivity C-reactive protein was recorded on day 1, 3 and 7 from drug administration</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Acute Physiology and Chronic Health Evaluation II (APACHE II) score on day 1, 3 and 7 from drug administration</measure>
    <time_frame>From study drug administration to days 7</time_frame>
    <description>The APACHE II scores on day 1, 3 and 7 were recorded</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The 28-day ventilator-free days (VFD)</measure>
    <time_frame>From study drug administration to day 28</time_frame>
    <description>Days alive and free from mechanical ventilation from study drug administration to day 28</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The 28-day mortality</measure>
    <time_frame>From study drug administration to day 28</time_frame>
    <description>Death of any cause from study drug administration to day 28</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The 90-day mortality</measure>
    <time_frame>From study drug administration to day 90</time_frame>
    <description>Death of any cause from study drug administration to day 90</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">238</enrollment>
  <condition>ARDS</condition>
  <arm_group>
    <arm_group_label>Sivelestat sodium</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Sivelestat sodium 0.2mg/kg.h</description>
  </arm_group>
  <arm_group>
    <arm_group_label>placebo</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>The same amount of NS containing only sivelestat sodium excipients</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sivelestat sodium</intervention_name>
    <description>Sivelestat sodium 0.2mg/kg.h for 1-7 days</description>
    <arm_group_label>Sivelestat sodium</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>The same amount of NS containing only sivelestat sodium excipients</description>
    <arm_group_label>placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Within 24 hours after admission, sepsis 3.0 diagnostic criteria were met;&#xD;
&#xD;
          -  The patients or their family members fully understand the purpose and significance of&#xD;
             the trial, voluntarily participate in the clinical trial, and sign the informed&#xD;
             consent.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients with ARDS were identified at the time of admission;&#xD;
&#xD;
          -  Patients who explicitly refused mechanical ventilation;&#xD;
&#xD;
          -  Patients with 3 or more extrapulmonary organ injuries and organ failure(single organ&#xD;
             SOFA score ≥ 3);&#xD;
&#xD;
          -  Patients who need home oxygen therapy or with home mechanical ventilation (by&#xD;
             tracheotomy or noninvasive ventilation, but excluding CPAP / BiPAP, only for patients&#xD;
             with obstructive sleep apnea);&#xD;
&#xD;
          -  The patient whose expected survival time was less than 48 hours;&#xD;
&#xD;
          -  Pregnant women and lactating women;&#xD;
&#xD;
          -  Other conditions judged by the researcher not suitable for inclusion.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Liu ling, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Department of Critical Care Medicine, Zhongda Hospital, School of Medicine, Southeast University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Liu ling, MD</last_name>
    <phone>+86-25-83262552</phone>
    <email>liulingdoctor@126.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Yang yi, MD</last_name>
    <phone>+86-25-83262552</phone>
    <email>yiyiyang2004@163.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Nanjing Zhong-Da Hospital, Southeast University</name>
      <address>
        <city>Nanjing</city>
        <state>Jiangsu</state>
        <zip>210009</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ling Liu, pHd</last_name>
      <phone>+86-25-83262550</phone>
      <email>liulingdoctor@gmail.com</email>
    </contact>
    <contact_backup>
      <last_name>Yang Yi, pHd</last_name>
      <phone>+86-25-83262552</phone>
      <email>yiyiyang2004@gmail.com</email>
    </contact_backup>
    <investigator>
      <last_name>Ling Liu, pHd</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>July 13, 2021</study_first_submitted>
  <study_first_submitted_qc>July 13, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">July 22, 2021</study_first_posted>
  <last_update_submitted>November 12, 2021</last_update_submitted>
  <last_update_submitted_qc>November 12, 2021</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 19, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Southeast University, China</investigator_affiliation>
    <investigator_full_name>Ling Liu</investigator_full_name>
    <investigator_title>professor</investigator_title>
  </responsible_party>
  <keyword>Sepsis</keyword>
  <keyword>Respiratory Failure</keyword>
  <keyword>ARDS</keyword>
  <keyword>efficacy</keyword>
  <keyword>Sivelestat sodium</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sepsis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sivelestat</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

